186
Views
4
CrossRef citations to date
0
Altmetric
Gastrointestinal Physiology

Heparin-binding EGF-like factor augments esophageal epithelial cell proliferation, migration and inhibits TRAIL-mediated apoptosis via EGFR/MAPK signaling

, , , , , , , , , , , , , , , , , & show all
Pages 1350-1359 | Received 01 Apr 2010, Accepted 07 Jun 2010, Published online: 01 Jul 2010

References

  • Nishi E, Prat A, Hospital V, Elenius K, Klagsbrun M. N-arginine dibasic convertase is a specific receptor for heparin-binding EGF-like growth factor that mediates cell migration. EMBO J 2001;20:3342–50.
  • Iwamoto R, Mekada E. ErbB and HB-EGF signaling in heart development and function. Cell Struct Funct 2006;31:1–14.
  • Fitsialos G, Chassot AA, Turchi L, Dayem MA, LeBrigand K, Moreilhon C, Transcriptional signature of epidermal keratinocytes subjected to in vitro scratch wounding reveals selective roles for ERK1/2, p38, and phosphatidylinositol 3-kinase signaling pathways. J Biol Chem 2007;282:15090–102.
  • Xie H, Wang H, Tranguch S, Iwamoto R, Mekada E, Demayo FJ, Maternal heparin-binding-EGF deficiency limits pregnancy success in mice. Proc Natl Acad Sci USA 2007;104:18315–20.
  • Révillion F, Lhotellier V, Hornez L, Bonneterre J, Peyrat JP. ErbB/HER ligands in human breast cancer, and relationships with their receptors, the bio-pathological features and prognosis. Ann Oncol 2008;19:73–80.
  • Lu X, Wang Q, Hu G, Van Poznak C, Fleisher M, Reiss M, ADAMTS1 and MMP1 proteolytically engage EGF-like ligands in an osteolytic signaling cascade for bone metastasis. Genes Dev 2009;23:1882–94.
  • Wang F, Liu R, Lee SW, Sloss CM, Couget J, Cusack JC. Heparin-binding EGF-like growth factor is an early response gene to chemotherapy and contributes to chemotherapy resistance. Oncogene 2007;26:2006–16.
  • Raab G, Klagsbrun M. Heparin-binding EGF-like growth factor. Biochim Biophys Acta 1997;1333:F179–99.
  • Katayama M, Kan M. Heparin-binding (fibroblast) growth factors are potential autocrine regulators of esophageal epithelial cell proliferation. In Vitro Cell Dev Biol 1991;27:533–41.
  • Freeman MR, Yoo JJ, Raab G, Soker S, Adam RM, Schneck FX, Heparin-binding EGF-like growth factor is an autocrine growth factor for human urothelial cells and is synthesized by epithelial and smooth muscle cells in the human bladder. J Clin Invest 1997;99:1028–36.
  • Hashimoto K, Higashiyama S, Asada H, Hashimura E, Kobayashi T, Sudo K, Heparin-binding epidermal growth factor-like growth factor is an autocrine growth factor for human keratinocytes. J Biol Chem 1994;269:20060–6.
  • Zushi S, Shinomura Y, Kiyohara T, Miyazaki Y, Tsutsui S, Sugimachi M, Role of heparin-binding EGF-related peptides in proliferation and apoptosis of activated ras-stimulated intestinal epithelial cells. Int J Cancer 1997;73:917–23.
  • Leach RE, Kilburn BA, Petkova A, Romero R, Armant DR. Diminished survival of human cytotrophoblast cells exposed to hypoxia/reoxygenation injury and associated reduction of heparin-binding epidermal growth factor-like growth factor. Am J Obstet Gynecol 2008;198:471.e1–7.
  • Chen X, Raab G, Deutsch U, Zhang J, Ezzell RM, Klagsbrun M. Induction of heparin-binding EGF-like growth factor expression during myogenesis. Activation of the gene by MyoD and localization of the transmembrane form of the protein on the myotube surface. J Biol Chem 1995;270:18285–94.
  • Takeuchi K, Motoda Y, Ito F. Role of transcription factor activator protein 1 (AP1) epidermal growth factor-mediated protection against apoptosis induced by a DNA-damaging agent. FEBS J 2006;273:3743–55.
  • Yan F, Cao H, Chaturvedi R, Krishna U, Hobbs SS, Dempsey PJ, Epidermal growth factor receptor activation protects gastric epithelial cells from Helicobacter pylori-induced apoptosis. Gastroenterology 2009;136:1297–307.
  • Yin J, Yu FS. ERK1/2 mediates wounding- and G-protein-coupled receptor ligands-induced EGFR activation via regulating ADAM17 and HB-EGF shedding. Invest Ophthalmol Vis Sci 2009;50:132–9.
  • Frenzel A, Grespi F, Chmelewskij W, Villunger A. Bcl2 family proteins in carcinogenesis and the treatment of cancer. Apoptosis 2009;14:584–96.
  • Tucker CA, Kapanen AI, Chikh G, Hoffman BG, Kyle AH, Wilson IM, Silencing Bcl-2 in models of mantle cell lymphoma is associated with decreases in cyclin D1, nuclear factor-kappaB, p53, bax, and p27 levels. Mol Cancer Ther 2008;7:749–58.
  • Qiu J, Xiao J, Han C, Li N, Shen X, Jiang H, Cao X. Potentiation of TNF-{alpha}-induced tumor cell apoptosis by a small-molecule inhibitor for anti-apoptotic protein hPEBP4. J Biol Chem 2010;285:12241–7.
  • Wiley SR, Schooley K, Smolak PJ, Din WS, Huang CP, Nicholl JK, Identification and characterization of a new member of the TNF family that induces apoptosis. Immunity 1995;3:673–82.
  • Teraishi F, Kagawa S, Watanabe T, Tango Y, Kawashima T, Umeoka T, ZD1839 (Gefitinib, ‘Iressa’), an epidermal growth factor receptor-tyrosine kinase inhibitor, enhances the anti-cancer effects of TRAIL in human esophageal squamous cell carcinoma. FEBS Lett 2005;579:4069–75.
  • Zhang H, Berezov A, Wang Q, Zhang G, Drebin J, Murali R, Greene MI. ErbB receptors: from oncogenes to targeted cancer therapies. J Clin Invest 2007;117:2051–8.
  • Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004;350:2129–39.
  • Lurje G, Lenz HJ. EGFR signaling and drug discovery. Oncology 2009;77:400–10.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.